SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Telegram Restored on Apple App Store After Temporary Removal 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
DUBLIN, Ireland, April 09, 2018 -- Horizon Pharma plc (Nasdaq:HZNP) announced today that its first-quarter financial results will be released on Wednesday, May 9, 2018. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
The live webcast and replay may be accessed at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes before the live webcast to ensure adequate time for any software download that may be needed to access the webcast.
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Investors:
Tina Ventura
Senior Vice President,
Investor Relations
[email protected]
Ruth Venning
Executive Director,
Investor Relations
[email protected]
U.S. Media:
Geoff Curtis
Senior Vice President,
Corporate Affairs & Chief Communications Officer
[email protected]
Ireland Media:
Ray Gordon
Gordon MRM
[email protected]
